Alzamend Neuro Inc Ordinary Shares ALZN 深 沪
等待开盘 09-18 09:30:00 美东时间
2.5206
-0.099
-3.79%
华盛通- 最 高2.6199
- 今 开2.57
- 成交量 11.30万股
- 最 低 2.46
- 昨 收 2.62
- 总市值 791.44万
- 52周最高 17.10
- 市盈率 静 --
- 换手率 3.60%
- 52周最低 2.06
- 委 比 -65.22%
- 总股本 313.99万
- 历史最高 45292.50
- 量 比 1.46
- 振 幅 6.10%
- 历史最低 2.46
- 每 手 1
- 风险率 4.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alzamend Neuro Q1 EPS $(1.28) Misses $(0.69) Estimate
Alzamend Neuro (NASDAQ:ALZN) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(0.69) by 85.51 percent. This is a 88.79 percent increase over losses of $(11.42) per share from
09-11 04:41
Ascendiant Capital Maintains Buy on Alzamend Neuro, Lowers Price Target to $45
Ascendiant Capital analyst Edward Woo maintains Alzamend Neuro (NASDAQ:ALZN) with a Buy and lowers the price target from $180 to $45.
08-21 17:32
Alzamend Neuro Increases Common Stock Through Conversion
Alzamend Neuro ( ($ALZN) ) has issued an announcement. Between July 23, 2025, a...
08-02 05:06
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
Alzamend Neuro, Inc. will present a study at MHSRS 2025 comparing lithium brain-to-plasma exposure in PTSD patients using AL001 and lithium carbonate. AL001 is a novel lithium-delivery system designed to improve brain targeting and reduce systemic side effects. The study aims to establish optimal dosing for PTSD and other conditions. Alzamend is advancing clinical trials for AL001 to treat Alzheimer's, bipolar disorder, major depressive disorder,...
07-28 12:00
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
Alzamend Neuro reported financial results for the year ended April 30, 2025, highlighting $10.4 million in net cash from financing activities and $4.0 million in stockholder equity, including $3.9 million in cash. In May 2025, the company dosed the first healthy patient in its AL001 "Lithium in Brain" studies at Massachusetts General Hospital. Alzamend also completed its $5 million private placement in June 2025, months ahead of schedule, strengt...
07-23 12:00
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
Alzamend Neuro, Inc. has completed a $5 million private placement months ahead of schedule, with proceeds supporting five Phase II clinical trials for AL001 "Lithium in Brain" Studies at Massachusetts General Hospital. The trials target Alzheimer’s, bipolar disorder, major depressive disorder, and PTSD, with the first study expected to report results by year-end. CEO Stephan Jackman expressed gratitude to the investor for accelerating the program...
06-16 12:00
Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update
Alzamend Neuro stock rocketed on Thursday after the company announced an update...
05-29 21:25
Alzamend Neuro shares are trading higher after the company dosed the first patient in its Phase II clinical trial of AL001.
Alzamend Neuro shares are trading higher after the company dosed the first pati...
05-29 20:05
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
Alzamend Neuro, Inc. has dosed the first patient in its Phase II clinical trial of AL001, a novel lithium-delivery system, in healthy human subjects. This study, conducted at Massachusetts General Hospital, aims to compare AL001's effectiveness in delivering lithium to the brain versus traditional lithium salts, potentially reducing systemic side effects and eliminating the need for therapeutic drug monitoring (TDM). AL001 has shown promise in pr...
05-29 12:00
Alzamend Neuro Enrolls First Patient Of First Phase II Clinical Study Of AL001, In Healthy Human Subjects; Topline Data Expected By Year End
Topline data expected by year endHead-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy
05-19 20:02
